

# CITATION REPORT

List of articles citing

## Neovascular age-related macular degeneration: potential therapies

DOI: 10.2165/00003495-200868080-00002  
Drugs, 2008, 68, 1029-36.

**Source:** <https://exaly.com/paper-pdf/43859330/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
126	Endothelial nicotinic acetylcholine receptors and angiogenesis. <b>2008</b> , 18, 247-53		64
125	Antiviral potency of a siRNA targeting a conserved region of coxsackievirus A24. <b>2008</b> , 376, 389-94		13
124	Doxycycline-mediated inhibition of choroidal neovascularization. <b>2009</b> , 50, 5098-106		40
123	siRNA therapeutics for age-related macular degeneration: promises and pitfalls. <b>2009</b> , 4, 525-535		
122	Treatment of retinal diseases with VEGF antagonists. <b>2009</b> , 175, 253-67		35
121	Glioma angiogenesis: Towards novel RNA therapeutics. <b>2009</b> , 3, 230-5		34
120	[New aspects in the therapy of neovascular age related macular degeneration. Current position of the Retinological Society, the Germany Ophthalmologic Society and the Professional Union of Eye Doctors of Germany]. <b>2009</b> , 106, 457-64		4
119	The hunt for gene dopers. <b>2009</b> , 1, 311-22		11
118	Design and development of polymer conjugates as anti-angiogenic agents. <b>2009</b> , 61, 1159-76		74
117	The TOR pathway comes of age. <b>2009</b> , 1790, 1067-74		262
116	Blue light-filtering intraocular lenses: review of potential benefits and side effects. <b>2009</b> , 35, 1281-97		52
115	Strategies for targeted nonviral delivery of siRNAs in vivo. <b>2009</b> , 15, 491-500		86
114	Pazopanib: therapeutic developments. <b>2009</b> , 10, 3091-102		18
113	Intravitreal injection of therapeutic agents. <b>2009</b> , 29, 875-912		173
112	Strategies for inhibiting vascular endothelial growth factor. <b>2009</b> , 29, S15-7		2
111	Anti-VEGF therapy in proliferative diabetic retinopathy. <b>2009</b> , 49, 95-107		28
110	Bevasiranib for the treatment of wet, age-related macular degeneration. <b>2010</b> , 2, 75-83		74

109	[Neovascular age-related macular degeneration under anti-angiogenic therapy : Subretinal fluid is a relevant prognostic parameter]. <b>2010</b> , 107, 158-64	8
108	Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. <b>2010</b> , 144, 134-43	124
107	Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo. <b>2010</b> , 17, 128-36	18
106	Targeting non-malignant disorders with tyrosine kinase inhibitors. <b>2010</b> , 9, 956-70	102
105	VEGF Trap(R1R2) suppresses experimental corneal angiogenesis. <b>2010</b> , 20, 48-54	30
104	A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. <b>2010</b> , 51, 6009-17	72
103	Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. <b>2010</b> , 2010,	136
102	Nucleic Acid-Based Therapies. <b>2010</b> , 233-260	
101	Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals. <b>2011</b> , 25, 171-89	1
100	Toxicological considerations for intravitreal drugs. <b>2011</b> , 7, 1021-34	13
99	[AMD: Future therapies]. <b>2011</b> , 34, 498-501	
98	Management of Neovascular AMD. <b>2011</b> , 79-98	
97	[Potential of liposomes for the intravitreal injection of therapeutic molecules]. <b>2011</b> , 69, 100-7	5
96	Genetic predictors of response to photodynamictherapy. <b>2011</b> , 15, 195-210	7
95	[Age-related macular degeneration: analysis of the results of ranibizumab therapy]. <b>2011</b> , 136, 128-9	
94	Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. <b>2011</b> , 56, 95-113	209
93	Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. <b>2011</b> , 155, 60-6	81
92	Monocyte/macrophages promote vasculogenesis in choroidal neovascularization in mice by stimulating SDF-1 expression in RPE cells. <b>2011</b> , 249, 1667-79	31

91	Aging and cancer: can mTOR inhibitors kill two birds with one drug?. <b>2011</b> , 6, 41-51	20
90	Research resource: nuclear receptor atlas of human retinal pigment epithelial cells: potential relevance to age-related macular degeneration. <b>2011</b> , 25, 360-72	47
89	New short interfering RNA-based therapies for glomerulonephritis. <b>2011</b> , 7, 407-15	9
88	Transcriptional regulation of bone morphogenetic protein 4 by tumor necrosis factor and its relationship with age-related macular degeneration. <b>2011</b> , 25, 2221-33	19
87	Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization. <b>2011</b> , 286, 20991-1001	28
86	Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. <b>2012</b> , 53, 4433-41	153
85	Polyethylene glycol-modified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization. <b>2012</b> , 342, 131-9	31
84	Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors. <b>2012</b> , 30, 49-61	16
83	Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases. <b>2012</b> , 2, 3	16
82	Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration. <b>2012</b> , 47, 227-35	18
81	Prevention of VEGF-induced growth and tube formation in human retinal endothelial cells by aldose reductase inhibition. <b>2012</b> , 26, 369-77	22
80	Aflibercept for intravitreal injection: in neovascular age-related macular degeneration. <b>2012</b> , 29, 839-46	15
79	Treatment of dry age-related macular degeneration with dobesilate. <b>2012</b> , 2012,	6
78	The development of encapsulated cell technologies as therapies for neurological and sensory diseases. <b>2012</b> , 160, 3-13	45
77	Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration. <b>2013</b> , 30, 331-58	35
76	Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo. <b>2013</b> , 10, 18-25	40
75	Regression of choroidal neovascularization in response to systemic chemotherapy for cancer. <b>2013</b> , 48, e80-2	
74	Pharmacotherapy of Age-Related Macular Degeneration. <b>2013</b> , 1213-1255	5

73	Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling. <b>2013</b> , 29, 268-274	
72	Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin. <b>2013</b> , 29, 493-500	29
71	Antiangiogenesis effects of endostatin in retinal neovascularization. <b>2013</b> , 29, 619-26	31
70	Aflibercept in wet AMD: specific role and optimal use. <b>2013</b> , 7, 711-22	77
69	Nanoscale Diblock copolymer micelles: characterizations and estimation of the effective diffusion coefficients of biomolecules release through cylindrical diffusion model. <i>PLoS ONE</i> , <b>2014</b> , 9, e105234	3-7 2
68	Intravitreal anti-vascular endothelial growth factor treatment for retinal diseases. <b>2014</b> , 57, 614	
67	Deletion of hemojuvelin, an iron-regulatory protein, in mice results in abnormal angiogenesis and vasculogenesis in retina along with reactive gliosis. <b>2014</b> , 55, 3616-25	11
66	Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. <b>2014</b> , CD011230	79
65	Particle-stabilized emulsion droplets for gravity-mediated targeting in the posterior segment of the eye. <b>2014</b> , 3, 1272-82	33
64	Trophic factors in the pathogenesis and therapy for retinal degenerative diseases. <b>2014</b> , 59, 134-65	75
63	Finding the Optimal Treatment Plan for Exudative AMD: A review of Current Anti-VEGF Dosing Regimens. <b>2015</b> , 55, 103-12	1
62	Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Resistant to Bevacizumab and Ranibizumab. <b>2015</b> , 56, 1359	10
61	Advances in pharmacotherapy for wet age-related macular degeneration. <b>2015</b> , 16, 1769-81	23
60	Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration. <b>2015</b> , 15, 1349-58	16
59	Recent developments in ocular drug delivery. <b>2015</b> , 23, 597-604	40
58	Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration. <b>2015</b> , 8, 541-8	25
57	Age related macular degeneration: challenge for future: Pathogenesis and new perspectives for the treatment. <b>2015</b> , 6, 69-75	24
56	Association between Vascular Endothelial Growth Factor Polymorphisms and Age-Related Macular Degeneration: An Updated Meta-Analysis. <b>2016</b> , 2016, 8486406	11

55	Antisense molecules: A new class of drugs. <b>2016</b> , 137, 1334-46	40
54	The mTOR Pathway and Aging. <b>2016</b> , 55-81	3
53	MicroRNA-processing Enzymes Are Essential for Survival and Function of Mature Retinal Pigmented Epithelial Cells in Mice. <b>2017</b> , 292, 3366-3378	20
52	Differentially cleaving peptides as a strategy for controlled drug release in human retinal pigment epithelial cells. <b>2017</b> , 251, 37-48	10
51	Intracellular enzymes of the retinal pigment epithelial cells for controlled drug delivery. <b>2017</b> , 251, 102	
50	Magnetic nanoparticles: a strategy to target the choroidal layer in the posterior segment of the eye. <b>2017</b> , 7, 43092	20
49	Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan. <b>2017</b> , 20, 204-212	8
48	Recent perspectives on the delivery of biologics to back of the eye. <b>2017</b> , 14, 631-645	36
47	Comparison of Choroidal Thickness Change between Ranibizumab and Aflibercept in Age-related Macular Degeneration: Six Month Results. <b>2017</b> , 58, 296	1
46	Human serum albumin nanoparticles for ocular delivery of bevacizumab. <b>2018</b> , 541, 214-223	37
45	Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy. <b>2018</b> , 38, 829-869	75
44	One-step solid-oil-water emulsion for sustained bioactive ranibizumab release. <b>2018</b> , 15, 1143-1156	4
43	Berberine Protects Human Retinal Pigment Epithelial Cells from Hydrogen Peroxide-Induced Oxidative Damage through Activation of AMPK. <b>2018</b> , 19,	19
42	Systemic side effects after intravitreal administration of anti-vascular endothelial growth factors for neovascular age-related macular degeneration. <b>2019</b> , 33, 110-116	
41	Protective Effects of Curcumin Ester Prodrug, Curcumin Diethyl Disuccinate against HO-Induced Oxidative Stress in Human Retinal Pigment Epithelial Cells: Potential Therapeutic Avenues for Age-Related Macular Degeneration. <b>2019</b> , 20,	23
40	In vivo and in vitro toxicity evaluation of liposome-encapsulated sirolimus. <i>International Journal of Retina and Vitreous</i> , <b>2019</b> , 5, 35	2.9 9
39	Hypoxic drive caused type 3 neovascularization in a preclinical model of exudative age-related macular degeneration. <b>2019</b> , 28, 3475-3485	5
38	In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization. <i>Experimental Eye Research</i> , <b>2019</b> , 185, 107697	3.7 16

37	Intravitreal conbercept injection for neovascular age-related macular degeneration. <b>2019</b> , 12, 252-257	6
36	Retinal Image Classification via Vasculature-Guided Sequential Attention. <b>2019</b> ,	1
35	Evolution of intravitreal therapy for retinal and macular disorders. <b>2020</b> , 48, 300060518771411	1
34	Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration: Systematic Literature Review and Expert Opinion. <b>2020</b> , 127, 648-659	20
33	Anti-integrin therapy for retinovascular diseases. <b>2020</b> , 29, 935-945	13
32	Fucoidans as Potential Therapeutics for Age-Related Macular Degeneration-Current Evidence from In Vitro Research. <b>2020</b> , 21,	4
31	Apigenin and Ethaverine Hydrochloride Enhance Retinal Vascular Barrier In Vitro and In Vivo. <b>2020</b> , 9, 8	4
30	Unique optical coherence tomographic features in age-related macular degeneration. <b>2020</b> , 65, 451-457	8
29	Xentry-Gap19 inhibits Connexin43 hemichannel opening especially during hypoxic injury. <b>2020</b> , 10, 751-765	6
28	Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy.. <b>2022</b> , 9, 62-79	11
27	Factors of Anti-Vascular Endothelial Growth Factor Therapy Withdrawal in Patients with Neovascular Age-Related Macular Degeneration: Implications for Improving Patient Adherence. <b>2021</b> , 10,	3
26	Protective Mechanism of Berberine on Human Retinal Pigment Epithelial Cells against Apoptosis Induced by Hydrogen Peroxide via the Stimulation of Autophagy. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2021</b> , 2021, 7654143	6.7 3
25	Perspectives of people with late age-related macular degeneration on mental health and mental wellbeing programmes: a qualitative study. <i>Ophthalmic and Physiological Optics</i> , <b>2021</b> , 41, 255-265	4.1 3
24	A Humanized Antibody against LRG1 that Inhibits Angiogenesis and Reduces Retinal Vascular Leakage.	9
23	CCR3 and choroidal neovascularization. <i>PLoS ONE</i> , <b>2011</b> , 6, e17106	3.7 29
22	Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye. <i>PLoS ONE</i> , <b>2011</b> , 6, e21411	3.7 57
21	Endoplasmic reticulum stress in age-related macular degeneration: trigger for neovascularization. <i>Molecular Medicine</i> , <b>2010</b> , 16, 535-42	6.2 98
20	Phosphorylation of STAT3 and ERBB2 mediates hypoxia-induced VEGF release in ARPE-19 cells. <i>Molecular Medicine Reports</i> , <b>2020</b> , 22, 2733-2740	2.9 1

19	Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2015</b> , 46, 195-200	1.4	10
18	Neue Therapieoptionen bei retinalen Erkrankungen: Was bringt die Zukunft?. <b>2011</b> , 109-130		
17	What is the role of CCR3 in choroidal neovascularization?. <i>Advances in Experimental Medicine and Biology</i> , <b>2012</b> , 723, 279-84	3.6	
16	Lack of association of CFD polymorphisms with advanced age-related macular degeneration. <i>Molecular Vision</i> , <b>2010</b> , 16, 2273-8	2.3	6
15	Vascular endothelial growth factors and their inhibitors in ocular neovascular disorders. <i>Journal of Ophthalmic and Vision Research</i> , <b>2009</b> , 4, 105-14	1.2	9
14	The effects of small interfering RNA-targeting tissue factor on an in vitro model of neovascularization. <i>Molecular Vision</i> , <b>2013</b> , 19, 1296-303	2.3	9
13	Pazopanib Selectively Inhibits Choroidal Vascular Endothelial Cell Proliferation and Promotes Apoptosis. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , <b>2020</b> , 9, 7-14	1.4	
12	Current Management of Diabetic Macular Edema.		1
11	Clinical validation of saliency maps for understanding deep neural networks in ophthalmology.. <i>Medical Image Analysis</i> , <b>2022</b> , 77, 102364	15.4	4
10	Retinal layer segmentation in optical coherence tomography (OCT) using 3D deep-convolutional regression network for patients with Age-related Macular Degeneration. <i>Biomedical Optics Express</i> ,	3.5	3
9	Therapeutic potential of topical administration of siRNAs against HIF-1 $\beta$ for corneal neovascularization.. <i>Experimental Eye Research</i> , <b>2022</b> , 219, 109036	3.7	0
8	Impact of Early COVID-19 Pandemic on Common Ophthalmic Procedures Volumes: A US Claims-Based Analysis.. <i>Ophthalmic Epidemiology</i> , <b>2021</b> , 1-9	1.9	0
7	Findings of uncertain significance by optical coherence tomography (OCT) as prognostic factors in neovascular age-related macular degeneration (nAMD) treated with ranibizumab.. <i>International Journal of Retina and Vitreous</i> , <b>2022</b> , 8, 29	2.9	
6	Gene-independent therapeutic interventions to maintain and restore light sensitivity in degenerating photoreceptors.. <i>Progress in Retinal and Eye Research</i> , <b>2022</b> , 101065	20.5	1
5	Properties of Cephalopod Skin Ommochromes to Inhibit Free Radicals, and the Maillard Reaction and Retino-Protective Mechanisms in Cellular Models Concerning Oxidative Stress, Angiogenesis, and Inflammation. <b>2022</b> , 11, 1574		
4	Risk factors and clinical significance of prechoroidal cleft in eyes with neovascular age-related macular degeneration in Caucasian patients.		0
3	Structure-Oriented Transformer for retinal diseases grading from OCT images. <b>2023</b> , 152, 106445		0
2	Exploring challenges to nutrition intervention adherence using COM-B model among patients with wet age-related macular degeneration: a qualitative study. <b>2022</b> , 12, e064892		0



1 Advances in Polysaccharide- and Synthetic Polymer-Based Vitreous Substitutes. **2023**, 15, 566

o